CellaVision quantifies the outlook for the first quarter of 2017. Sales exceeding SEK 93 million in the first quarter of 2017

2017-04-07 - English

The information was released for public disclosure on April 7, 2017 at 08.20 CET.

CellaVision AB (publ) announces preliminary figures due to the company's significantly increased sales in the first quarter of 2017 compared to the same period last year. The company announces preliminary net sales exceeding SEK 93 million (58.3) with a revenue growth of at least 60 percent and an operating profit in excess of SEK 34 million (13.9).

CellaVision has an uneven order flow and revenue over the year, and the variation in order volumes in individual quarters may be significant. The variations between different geographical regions may also be substantial.

During the first quarter of 2017, CellaVision had exceptional sales in the Americas and APAC and a more stable development in EMEA compared to the same period last year. The strong regional sales development is the main reason for the increase in sales for the first quarter of 2017.

The company will publish its interim report for the first quarter of 2017 on May 4, 2017.

For more information please contact:
Zlatko Rihter, President and Chief Executive Officer, CellaVision AB
Phone: +46 (0) 733- 62 11 06 | E-mail: zlatko.rihter@cellavision.com

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replaces manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the market support organizations in the US, Canada, China, Sweden, Japan, Dubai, Korea, Australia and France. In 2016 sales were SEK 265 million and the company's growth target is 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Small Cap list. Read more at www.cellavision.com

PDF version: Pdf

Subscribe to updates

It's possible to subscribe to CellaVision's press releases, financial information by e-mail and SMS.

Click here to register


Information request

Are you looking for some particular information about our company or our business?

Click here to get in touch


Analyst

ABG Sundal Collier AB
Sten Gustafsson
+46 8 566 286 93

Pareto Securities AB
Christian Lee
+46 8 402 52 67

 

Access our Student Resources

To access this resource, please provide the following information about yourself.